
A human study found no age-related drop in healthy adults’ whole-blood NAD. Its cardiovascular links raise research questions, not a validated test.

On November 4, 2026, Nature Metabolism published Whole-blood NAD levels track cardiovascular disease but not chronological age. The research involved adults recruited in Lithuania between 2023 and 2025.
The study’s central finding was that whole-blood NAD showed no significant association with age in healthy men and increased modestly with age in healthy women. The researchers estimated an age-associated increase of 0.07 μM per year in healthy women. Lower whole-blood NAD was instead associated with cardiovascular disease, including comparisons involving hypertension. For longevity research, the authors’ conclusion challenges the assumption that healthy adults generally develop a whole-blood NAD deficit as they grow older.
Conducted in humans: an observational study with a cross-sectional main analysis.
The main population analysis included 1,068 adults: 636 women and 432 men. Samples were collected under standardized morning and fasting conditions. Across the study programme, the researchers reported 1,340 measurements.
The authors also described small exploratory components involving supplement users. These addressed a different question from the population analysis. The population comparison examined patterns across participants, while the exploratory observations described measured blood changes during supplement use.
The researchers place their findings within an unsettled field of human blood NAD research. They say the absence of an age-related decline independently replicated earlier work using a different method and population. That context is useful when weighing claims built around blood NAD, rather than judging a result only by how surprising its headline sounds.
Reading the paper therefore requires keeping three questions separate: how the measurement relates to age; how it differs between disease groups; and whether changing it improves health. Those questions concern different outcomes. A persuasive answer to one does not automatically answer the others.
The practical response is to identify the exact question a claim is trying to answer. A statement about chronological age should name age as its endpoint. A cardiovascular claim should specify the clinical outcome it aims to inform. A supplement claim should identify the human benefit being tested rather than substituting a change in the measured blood value.
This is also a useful framework for interpreting blood-based aging indicators. Start with the sample and measured substance. Then identify the population and outcome. Finally, ask whether the proposed use matches the evidence actually collected.
Applied here, that approach produces a more precise interpretation than either dismissing NAD biology or promoting NAD testing. The healthy-adult findings challenge an assumed universal blood deficit. The cardiovascular findings identify an association worth investigating. Each result has a distinct research role.
For readers interested in heart health, the appropriate context is evidence for cardiovascular prevention rather than treating an emerging laboratory association as a replacement for established assessment. Personal decisions about testing or supplements belong with a qualified healthcare professional who can consider the individual’s broader health context.
The next step is prospective research with repeated measurements to test cardiovascular prediction, alongside adequately powered trials that assess whether NAD-related interventions improve meaningful health outcomes safely.
Blood NAD headlines require a choice between reporting a laboratory association and implying a health benefit; AgeAmaze explains the research behind that distinction. Its readable coverage helps skeptical adults assess overstated biological-age and supplement claims by showing how strongly a finding supports an emerging intervention.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog